[Click eStock] "Gemvax to Reveal Full Data and Mechanism of Action from Phase 2 Clinical Trial"

[Asia Economy Reporter Hyungsoo Park] Hanyang Securities introduced on the 21st that GemVax will soon publish a paper on the full data of the Phase 2 clinical trial for Alzheimer's and research results on the mechanism of action.

Byungyong Oh, a researcher at Hanyang Securities, said, "GemVax announced the topline (primary endpoint) results of the Phase 2 clinical trial for the Alzheimer's new drug ‘GV1001’ in December last year," adding, "The research team led by Professor Seongho Ko of Hanyang University Hospital, who was the principal investigator, submitted a paper on the full clinical data and mechanism of action to a top-tier global academic journal last June."

He continued, "Since the topline data was excellent, the value of the new drug will increase once the results regarding the secondary endpoints and mechanism of action are revealed."

He also emphasized, "If it is published in a global academic journal, that itself is evidence that ‘GV1001’ has been recognized overseas."

Researcher Oh stated, "GemVax is planning a Phase 3 clinical trial based on the CSR report for the Phase 2 trial submitted last July," and "They plan to submit the Phase 3 IND to the Ministry of Food and Drug Safety by next month."

This content was produced with the assistance of AI translation services.